PETS
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

PetMed Express, Inc. is a direct-to-consumer pet health and wellness retailer that operates as a licensed online pharmacy. The company sells prescription and generic medications, over-the-counter health products, vitamins, supplements, and pet food for dogs, cats, and horses. It serves customers across the United States and the U.S. Virgin Islands through its websites Petmeds.com and PetCareRx.com, mobile applications, and customer contact centers. The business handles end-to-end prescription verification by connecting customers with licensed veterinarians for approval before shipping. PetMed Express offers an AutoShip subscription service for recurring orders and provides educational content through pethealthmd.com. The company acquired PetCareRx, Inc. in April 2023 to expand its catalog of premium food, treats, and supplies. It partners with Pet Synergy Group to offer the PetAssure employee benefits program and collaborates with Dutch to provide online veterinary consultations. Founded in 1996, the company employs licensed pharmacists and maintains pharmacy locations accredited by the National Association of Boards of Pharmacy and LegitScript.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Internet Retail Homepage 1800petmeds.com
Sector Consumer Cyclical IR page investors.petmeds.com/overview/default.aspx
Tags
pet pharmacy, prescription medications, pet food, veterinary supplements, flea and tick prevention, auto-ship subscriptions, online veterinary services, pet wellness, PetMeds, PetCareRx, Petmeds.com, PetCareRx.com, pethealthmd.com, Pet Synergy Group, PetAssure, Dutch, Simparica TRIO, HEARTGARD Plus, NexGard, Apoquel, Credelio Quattro, NexGard Plus, Interceptor Plus
Press page —

Metrics

Valuation  
Market cap $ 30.541M
Market cap (USD) $ 30.541M
P/E -1.09
PEG —
P/BV 1.81
P/S 0.19
P/OCF -1.35
P/FCF -1.24
Dividend yield 43.5%
Turnover / mcap —
Returns  
ROE -100.4%
ROI -756.8%
ROIC -581.3%
Profit margin -32.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Revenue 179.021M 226.972M 281.064M 256.858M 273.417M 309.215M 284.125M 283.419M 273.8M 249.176M 234.684M 229.395M 233.391M 227.829M 238.25M 231.642M 219.412M 188.336M 162.246M 137.583M 108.358M 93.994M 54.975M
Net profit -57.286M -6.271M -7.464M 233K 21.1M 30.603M 25.851M 37.74M 37.283M 23.819M 20.567M 17.453M 17.972M 17.165M 16.659M 20.871M 22.976M 20.022M 14.444M 12.064M 8.01M 5.814M 3.258M
Free cash flow -33.009M -395K -194K 22.543M 16.746M 37.643M 36.533M 44.518M 36.676M 36.6M 923K 31.125M 13.461M 12.664M 19.686M 29.439M 11.758M 18.878M 15.539M 9.519M 8.177M 363.855K 225.705K

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Share price 2.28 4.19 4.79 16.24 25.8 35.18 28.78 22.78 41.75 20.14 17.91 16.52 13.41 13.41 12.39 17.81 18.5 13.07 11.13 19.65 — — —
Price performance 12m -0.46 -0.13 -0.71 -0.37 -0.27 0.22 0.26 -0.45 1.07 0.12 0.08 0.23 -0 0.08 -0.3 -0.16 0.42 0.17 -0.43 — — — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) 1.81M 2.29M 2.54M 3.84M 2.59M 1.91M 1.74M 3.28M 2.32M 1.91M
↳ YoY growth +4.9% +26.8% +10.9% +51.2% -32.7% -26.1% -9.0% +88.7% -29.4% -17.7%
↳ 5y CAGR +2.8% +9.8% +7.6% +14.8% +8.5% +1.1% -5.4% +5.2% -9.6% -5.9%
Lease liabilities (USD) — — — — — — 0.00 1.45M 996,000 535,000
Cash and deposits (USD) 58.7M 77.9M 101M 104M 119M 111M 104M 55.3M 54.7M 21.4M
Intangible assets (USD) 860,000 860,000 860,000 860,000 860,000 860,000 5.86M 11.2M 8.05M 5.49M
Right-of-use assets (USD) — — — — — — 0.00 1.43M 966,000 512,000
Cash flow detail
Operating cash flow (USD) 47.2M 37.4M 45.1M 38.8M 40.1M 18.5M 27.8M 4.32M 4.72M -28.4M
Purchases of property, plant and equipment (USD) -10.6M -703,000 -620,000 -2.31M -2.43M -1.75M -5.26M -4.51M -5.11M -4.62M
Change in receivables (cash effect) (USD) -505,000 -596,000 -335,000 -1.49M 1.13M 509,000 -41,000 -1.74M 601,000 445,000
Change in inventories (cash effect) (USD) — — — — — — 13.4M -6.42M 12.4M 471,000
Change in payables (cash effect) (USD) 10.2M 53,000 1M 3.38M 19.9M -12M -2.29M 6.1M -13.5M -2.66M
Dividends paid (cash effect) (USD) -15.5M -17.5M -21.9M -21.8M -22.7M -24.4M -24.5M -12.4M -181,000 -21,000
Share buybacks (cash effect) (USD) — — 0.00 -11.5M 0.00 0.00 — — — —
Income taxes paid (cash effect) (USD) -11.4M -18M -11.1M -7.14M -10M -6.09M -4.31M -130,000 -525,000 -52,000
Share-based compensation (USD) 1.94M 2.58M 3.1M 2.82M 3.31M 4.55M 6.62M 6.87M -6.59M 1.37M
Operating cash flow before change in receivables (USD) 47.7M 38M 45.5M 40.3M 38.9M 18M 27.8M 6.06M 4.12M -28.8M
Free cash flow (OCF - PPE - intangibles) (USD) 36.6M 36.7M 44.5M 36.5M 37.6M 16.7M 22.5M -194,000 -395,000 -33M
Income detail
Total comprehensive income (USD) 23.8M 37.3M 37.7M — — — — — — —
Comprehensive income to owners (USD) 23.8M 37.3M 37.7M — — — — — — —
Provision for credit losses (USD) 421,000 112,000 85,000 191,000 130,000 165,000 214,000 324,000 365,000 -36,000
Credit cost ratio (credit losses / average receivables) (%) 23.8% 5.5% 3.5% 6.0% 4.0% 7.3% 11.7% 12.9% 13.0% 1.7%
Reported May 23, 2017 May 29, 2018 May 25, 2021 May 26, 2020 May 25, 2021 May 24, 2022 Oct 14, 2025 Oct 14, 2025 Oct 14, 2025 Jun 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PetMeds® Announces Second Quarter Financial Results Bull 2 Bear 4 Results

Delray Beach, Florida, November 10, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026.

Quarterly Highlights

•For the second quarter ended September 30, 2026, net sales were $35.8 million compared to $44.4 million for the prior year period, a decrease of 19.4%, primarily driven by a decline in prescription medication sales and higher consumer promotional usage.

•Net loss for the quarter ended September 30, 2026, was $6.4 million, or $(0.31) per diluted share, compared to a net loss of $8.5 million, or $(0.41) per diluted share, for the prior year period. The decrease in net loss was primarily driven by lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by unfavorable product mix shift and lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.

•Adjusted EBITDA1 was $(3.6) million compared to $(2.3) million in the prior year period.

October 27, 2026

View All News

DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year ended September 30, 2026, on Tuesday, November 10, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.

Date: Tuesday, November 10, 2026
Time: 4:30pm Eastern Time (1:30pm Pacific Time)
U.S. dial-in number: 877-407-0789
International number: 201-689-8562
Webcast: 2Q Earnings Webcast

A telephonic replay of the conference call will also be available after 7:30 PM Eastern Time on the same day through November 24, 2026.

Toll-free replay number: 844-512-2921
International replay number: 412-317-6671
Replay passcode: 13763243

About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com .

Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
[email protected]

Primary Logo

Source: PetMed Express, Inc.

View All News

October 2, 2026

View All News

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.

The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as amended and restated, which was adopted by the Board of Directors in September 2024 and amended in September 2026. The restricted stock awards will vest over three years in equal one-third increments on each of the first three (3) anniversaries of the grant date, subject to continued employment with the Company on each vesting date. The PSUs granted to Mr. Willard each represent a contingent right to receive one share of the Company's common stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029. The awards were granted as a material inducement to employment with PetMeds, in accordance with Nasdaq Listing Rule 5635(c)(4).

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com .

Investor Contact
ICR, LLC
Reed Anderson
[email protected]

Primary Logo

Source: PetMed Express, Inc.

View All News

Prompts

PetMed Express, Inc. (ticker PETS), listed in United States.

ETFs Holding PetMed Express, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.06% 112,061 $ 211.795K Aug 31, 2026
BSVO 0.00% 95,153 $ 90K Nov 18, 2026